tirzepatide cardiovascular outcomes trial 2024

tirzepatide cardiovascular outcomes trial 2024 Long-awaited SURPASS-CVOT: with vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular

Name: tirzepatide cardiovascular outcomes trial 2024 Long-awaited SURPASS-CVOT: with vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular
Brand: actil.am
SKU: 17515561031
Price: 24.23 USD
Availability: InStock
Rating: 4.7281 (18 reviews)

SKU: 17515561031

4.7

USD24.23 USD67.23

Pay in 4 interest-free payments of $6.06 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Sep 1 - Sep 6

Description

Prescription drugs, particularly those that target specific biological pathways involved in obesity, such as GLP-1 receptor agonists, have gained significant attention for their proven effectiveness